FANSLOW; William C.

Patent Applications and Registrations

Patent applications and USPTO patent grants for FANSLOW; William C..The latest application filed is for "anti-pd1 and anti-ctla4 antibodies".

Company Profile

1.21.8

FANSLOW; William C. - Normandy Park WA
FANSLOW; WILLIAM C. - FEDERAL WAY WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-pd1 And Anti-ctla4 Antibodies App 20220135683 - LIU; Zhi ; et al.	2022-05-05
Anti-PD1 and anti-CTLA4 antibodies Grant 11,124,570 - Liu , et al. September 21, 2	2021-09-21
Anti-pd1 And Anti-ctla4 Antibodies App 20190276542 - LIU; Zhi ; et al.	2019-09-12
Novel Receptor That Binds Ctla-8 App 20100233186 - YAO; ZHENGBIN ; et al.	2010-09-16
Methods of inhibiting interleukin-17 receptor App 20090068737 - Yao; Zhengbin ; et al.	2009-03-12
Methods of treating asthma by administering interleukin-17 receptor Grant 7,432,237 - Yao , et al. October 7, 2	2008-10-07
Mouse CD40 ligand-specific antibodies and hybridomas Grant 7,309,489 - Armitage , et al. December 18, 2	2007-12-18
Methods of treating allergy by administering interleukin-17 receptor Grant 7,273,843 - Yao , et al. September 25, 2	2007-09-25
Methods of treating allergy by administering interleukin-17 receptor App 20040120899 - Yao, Zhengbin ; et al.	2004-06-24
Methods of treating asthma by administering interleukin-17 receptor App 20040120898 - Yao, Zhengbin ; et al.	2004-06-24
Methods of treating autoimmune disease by administering interleukin-17 receptor Grant 6,680,057 - Yao , et al. January 20, 2	2004-01-20
Methods Of Treating An Undesired Immune Response By Blocking The Binding 0f Cd40 Ligand To Cd40 App 20030091564 - ARMITAGE, RICHARD J. ; et al.	2003-05-15
Ligand for CD7 and methods for use thereof App 20020141999 - Lyman, Stewart D. ; et al.	2002-10-03
DNA encoding CD40 ligand, a cytokine that binds CD40 Grant 6,410,711 - Armitage , et al. June 25, 2	2002-06-25
Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells Grant 6,391,637 - Armitage , et al. May 21, 2	2002-05-21
Method of augmenting a vaccine response by administering CD40 ligand Grant 6,290,972 - Armitage , et al. September 18, 2	2001-09-18
Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L Grant 6,264,951 - Armitage , et al. July 24, 2	2001-07-24
Assay kits for detection and methods of inhibiting IL-17 binding Grant 6,197,525 - Yao , et al. March 6, 2	2001-03-06
Methods of treating graft rejection with the IL-17 receptor Grant 6,191,104 - Spriggs , et al. February 20, 2	2001-02-20
Methods of treating immune and inflammatory response with IL-17 receptors Grant 6,100,235 - Yao , et al. August 8, 2	2000-08-08
Receptor that binds IL-17 Grant 6,096,305 - Yao , et al. August 1, 2	2000-08-01
CD40 ligand polypeptide Grant 6,087,329 - Armitage , et al. July 11, 2	2000-07-11
Receptor that binds IL-17 Grant 6,072,033 - Yao , et al. June 6, 2	2000-06-06
Antibodies to the IL-17 receptor Grant 6,072,037 - Yao , et al. June 6, 2	2000-06-06
DNA encoding CD40 ligand, a cytokine that binds CD40 Grant 5,981,724 - Armitage , et al. November 9, 1	1999-11-09
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same Grant 5,962,406 - Armitage , et al. October 5, 1	1999-10-05
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same Grant 5,961,974 - Armitage , et al. October 5, 1	1999-10-05
Receptor that binds IL-17 Grant 5,869,286 - Yao , et al. February 9, 1	1999-02-09
Interleukin-4 binding protein-.gamma. Grant 5,223,605 - Fanslow , et al. June 29, 1	1993-06-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.